A low osmolar, nonionic, iodinated contrast agent, the OMNIPAQUE has been used in more than 250 million patients worldwide. Its indications include a broad range of intravascular diagnostic procedures such as coronary angiography, spinal cord imaging and body cavity procedures including shoulder and knee joints. The injection is approved for use in adults and children.
If you enjoy this content, please share it with a colleague
Technology | February 06, 2007
Injection Used to Visualize Vessels, Organs, Tumors
Related Content
On Jan. 10, 2024, Diagnostic and Interventional Cardiology presented a webinar on "Contrast Management in Modern PCI." ...
Sponsored Content | Webinar | Contrast Media Injectors
On Jan. 10, 2024, Diagnostic and Interventional Cardiology presented a webinar on "Contrast Management in Modern PCI." ...
May 3, 2016 — The global market for contrast media injectors is set to increase from $830 million in 2015 to almost $1.8 ...
October 1, 2015 — Galt Medical has partnered with Health Line International Corp. and launched the Nexus CT Midline ...
Feature | Contrast Media Injectors | Raissa Rocha and Dave Fornell
There have been several recent advances with contrast media injector technology, including cutting costs by reducing ...
Feature | Contrast Media Injectors | Dave Fornell
Automated contrast media injectors are used in cardiac imaging to help improve patient safety and enhance image quality ...
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now